Aligos Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for liver diseases and viral infections. Key pipeline assets include pevifoscorvir sodium (CAM-E) for chronic HBV infection in Phase 2 B-SUPREME study, ALG-055009 (THR-beta agonist) for MASH and obesity in Phase 2a, and ALG-097558 (coronavirus 3CL protease inhibitor) in Phase 2 for COVID-19. The company also maintains preclinical ASO platforms for HBV and HDV.
expected 2026-12-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-092614 | EDGAR | 99K words |
| 2025-03-10 | 2024-12-31 | 0000950170-25-035929 | EDGAR | 97K words |
| 2024-03-12 | 2023-12-31 | 0000950170-24-029953 | EDGAR | 101K words |
| 2023-03-09 | 2022-12-31 | 0000950170-23-007033 | EDGAR | 97K words |
| 2022-03-10 | 2021-12-31 | 0000950170-22-003365 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001564590-21-014872 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336851 | EDGAR | 69K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-268203 | EDGAR | 71K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104042 | EDGAR | 70K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063983 | EDGAR | 67K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122371 | EDGAR | 71K words |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091828 | EDGAR | 70K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054497 | EDGAR | 68K words |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058256 | EDGAR | 70K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038045 | EDGAR | 69K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017890 | EDGAR | 66K words |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021248 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014815 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-15 | 0001193125-26-391880 | EDGAR | 1K words |
| 2026-08-06 | 0001171843-26-005294 | EDGAR | 2K words |
| 2026-03-05 | 0001171843-26-001340 | EDGAR | 3K words |
| 2026-02-04 | 0001193125-26-037558 | EDGAR | 1K words |
| 2025-11-06 | 0001171843-25-007075 | EDGAR | 2K words |
| 2025-08-06 | 0001171843-25-005116 | EDGAR | 3K words |
| 2025-06-26 | 0001193125-25-148905 | EDGAR | 2K words |
| 2025-05-06 | 0001171843-25-002781 | EDGAR | 2K words |
| 2025-03-10 | 0001171843-25-001352 | EDGAR | 3K words |
| 2025-02-12 | 0001193125-25-024838 | EDGAR | 1K words |
87 total filings indexed. 59 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001799448 |
| Ticker | ALGS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.aligos.com |
| Listed | 2020-10-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALGS (~200 tokens, structured JSON with cryptographic provenance)